Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUDT21 siRNA for Refractory Retinoblastoma
NCT06424301Phase 1Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NUDT21 siRNA in retinoblastoma (Rb), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
NUDT21 siRNA
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT06424301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424301.